The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

In the latest trading session, Astrazeneca (AZN) closed at $72.66, marking a -1.38% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.4%. Elsewhere, the Dow ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a ...

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.